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Abstract. Cholangiocarcinoma is an uncommon primary 
malignancy of the biliary tract that is challenging to diagnose 
and treat effectively due to its relatively silent and late clinical 
presentation. The present study reports a case of a 60-year-old 
male with distal extrahepatic cholangiocarcinoma with a 
3-week history of painless obstructive jaundice symptoms 
and subjective weight loss. Imaging revealed an obstructing 
lesion in the common bile duct, just distal to the entrance of 
the cystic duct. Pathology revealed moderately differentiated 
cholangiocarcinoma with two positive proximal resection 
margins. The two positive resection margins presented a chal-
lenge during surgery and points to an urgent need for further 
studies to better illuminate diagnostic and therapeutic options 
for patients with similar clinicopathological presentation.
Introduction
Cholangiocarcinoma (CCA), an extremely rare and highly 
aggressive malignant tumor was first described in 1957 (1). 
They are cancers of the epithelial cells in the extrahepatic or 
intrahepatic biliary tree of the bile duct from the bile ductules 
to the Ampulla of Vatar (2-4). CCA is often diagnosed in 
patients >60 years and the prognosis is poor in the majority 
of cases (5,6). Furthermore, CCA is often difficult to diagnose 
and treat due to its growth pattern, silent nature (wherein its 
symptoms go unnoticed by the patient until the advanced 
stage), anatomical location, non‑specific clinical presentation 
and limited clinical approaches. CCA is the second most 
common primary hepatic tumor globally, accounting for 3% of 
all gastrointestinal tumors, though that rate is increasing (7,8). 
Worldwide, the highest CCA rates have been reported in 
Eastern Asia, particularly Thailand, where its high incidence 
is attributable to liver fluke infection (9). To the best of our 
knowledge, case reports of distal extrahepatic CCA with two 
positive resection margins are rare. This is the first reported 
CCA case from the Caribbean (30 island nations, population, 
39.8 million) and more specifically, Trinidad and Tobago 
(population, 1.3 million).
Case report
The present study presents a case of a distal extrahepatic 
cholangiocarcinoma with its imaging and clinicopathological 
details, as well as the epidemiology of CCA in Trinidad and 
Tobago. A 60-year-old male non-smoker of African and 
Indian ethnicity, with no previously known medical conditions 
presented to the Eric Williams Medical Sciences Complex, 
Champ Fleurs (Trinidad and Tobago) with a 3-week history 
of painless obstructive jaundice symptoms and subjective 
weight loss. The patient has a family history of breast, pros-
tate and lung cancer (Fig. 1). The patient's mother and an 
aunt succumbed to lung and breast cancer, respectively; the 
patient's father has prostate cancer and several of his uncles 
have prostate and/or colon cancer.
On examination, the patient had icterus and a palpable 
gallbladder. Complete blood count, renal function and inter-
national normalized ratio tests were normal, but his liver 
function tests were abnormal: Total bilirubin, 9.1 mg/dl and 
bilirubin, 4.5 mg/dl. Computed tomography (CT) of the chest, 
abdomen and pelvis scan revealed dilated intra-hepatic ducts, 
gallbladder, cystic duct and common hepatic duct, just distal to 
entrance of cystic duct (Fig. 2). Magnetic resonance cholangio-
pancreatography (MRCP) revealed an obstructing lesion in the 
common bile duct with proximal extent just distal to the cystic 
duct and distal extent just superior to the upper border of the 
pancreas (Fig. 3).
An initial bile duct excision was made 1 cm proximal to the 
tumor and distally down to the upper border of the pancreas. 
Kocherization of the duodenum allowed exposure of the retro-
peritoneum and visualization of the neighboring structures. 
A lymph node at station 8A was excised. Following bile duct 
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excision, imprint cytology demonstrated that both superior and 
inferior margins were invaded by the tumor. The proximal bile 
duct was re‑excised to the hepatic ductal confluence, however, 
this margin was also positive. A pancreaticoduodenectomy 
(Whipple procedure) was performed to gain a clear distal 
margin but no further resection was done on the proximal bile 
duct, due to the lack of intra-operative imprint cytology at that 
time leaving us unable to perform a right vs. left hepatectomy, 
as we were unsure which hepatic duct was involved. The 
MRCP demonstrated it was free of tumor and macroscopically 
both ducts appeared normal.
Macroscopically, the cut surface of common bile duct 
revealed an ulcero-proliferative lesion (3.0x2.0x1.5 cm), 
0.2 cm from the proximal bile duct margin and 1.0 cm from 
the distal bile duct margin. Histology revealed T2N1M0 
moderately differentiated CCA with a positive proximal resec-
tion margin and metastatic deposits in station 8A lymph node 
along with peri-neural invasion (Fig. 4). Post-operatively, the 
patient had bile noted from the drains with resolution after 
two weeks. Six-months postoperative, the patient is receiving 
adjuvant chemotherapy (capecitabine) and has completed 30 
cycles of external beam radiotherapy to the porta hepatis due 
to the positive proximal margin. At six months follow up, the 
patient showed small hepatic metastasis upon CT screening.
Discussion
In Trinidad and Tobago there were 65 reported CCA cases 
from 1995-2007, accounting for 0.41% of all incident cancer 
cases (personal communication from the Trinidad and 
Tobago National Cancer Registry). There was a slight male 
predilection (56.9%) and the overall average incident age 
was 60-69 years. The present case report, in addition to the 
majority of cases (66.1%) in TT originate in the extrahepatic 
bile duct, with the remaining cases occurring in the biliary 
track NOS (13.8%) followed by the Ampulla of Vater (0.2%). 
Forty-six percent of cases were diagnosed at autopsy and the 
majority of the other cases were diagnosed by histology of the 
primary tumor. The majority of cases occurred in nationals of 
African (63.1%), Indian (29.2%) then Mixed (African-Indian) 
ancestry (7.7%). This contrasts with data from the USA, where 
Hispanics and Asians have higher incident rates compared to 
African Americans (7).
The general risk factors for cholangiocarcinoma are 
primary sclerosing cholangitis (PSC), recurrent pyogenic 
cholangitis, hepatolithiasis, primary biliary cirrhosis, chole-
lithiasis, Asian liver flukes, biliary malformation (Caroli's 
disease, choledochal cysts), toxins (thorotrast, dioxin, poly-
vinyl chloride and heavy alcohol use), and viral infection 
(HIV, hepatitis B and hepatitis C and EBV) (10-14). There was 
no evidence that our patient was exposed to these risk factors. 
In fact, most CCA cases like the one presented in the current 
study arise de novo (12).
Clinical management of these cases is challenging and 
requires a multimodality approach. While surgical resection 
is an optimal treatment approach, many patients are not candi-
dates as the disease is often diagnosed at an advanced stage 
given that diagnostic symptoms like night sweats, malaise, 
jaundice, abdominal pain and cachexia are not uniquely infor-
mative (15). Another compounding factor is the possibility of 
metastatic spread to the hepatic vasculature, regional lymph 
nodes, lung, bones (especially vertebrae), adrenal system and 
brain.
Figure 1. Pedigree analysis of the patient.
Figure 2. Computed tomography showing the dilated intra-hepatic ducts, 
gallbladder (indicated by*), cystic duct and common hepatic duct, just distal 
to the entrance of the cystic duct.
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According to the 8th edition of the Union for Inter-
national Cancer Control-American Joint Committee on 
Cancer (UICC‑AJCC) classification there are two divisions 
of extrahepatic cholangiocarcinoma-distal and perihilar. 
For distal extrahepatic CCA, tumor depth invasion, number 
of lymph node metastases, perineural, microscopic vascular 
invasion, R0 resection and pancreatic invasion are reported to 
be predictors of long term survival (16-23). A single positive 
bile duct resection margin is usually correlated with increased 
risk of recurrence and poor prognosis, as is a positive lymph 
node (24,25). A recent study that examined 27 patients with 
distal bile duct cancer who underwent pancreatoduodenectomy 
with extended lymphadenectomy identified that factors for 
improved survival included up to two positive nodes, negative 
resection margins, and clinical administration of postoperative 
adjuvant chemotherapy (21).
Generally the prognosis for CCA is poor with 5-year 
survival of 5-10%, and a median survival of 3-6 months if 
unresectable (13,26). Post surgery survival time depends on 
a thorough resection with negative resection margins. It is 
well established that recurrences occur in 60-80% of patients 
within two years after the initial surgery (27). In the present 
case, given that the regional lymph nodes were positive our 
challenge was deciding how far to resect. We had to weigh the 
probability of local vs. distant recurrence and the morbidity 
and potential mortality of trying to gain a R0 proximal margin. 
Figure 3. MRCP scan showing the mass in the proximal CBD. MRCP, magnetic resonance cholangiopancreatography. The normal distal bile duct (indicated 
by X), gall bladder (indicated by*), and dilated proximal hepatic duct (indicated by**) are noted.
Figure 4. Moderately differentiated adenocarcinoma with involvement of proximal and distal surgical resected margins of the common bile duct. (A) Proximal 
bile duct margin. H&E, staining. Magnification, x40. (B) Distal bile duct margin. H&E staining. Magnification, x10. (C) Distal bile duct margin showing neo-
plastic cells at the margin (arrowhead). H&E staining. Magnification, x100. (D) Characteristic perineural invasion (arrowhead). H&E staining. Magnification, 
x40. H&E, hematoxylin and eosin.
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It was ultimately decided that the probability of distant recur-
rence outweighed that of local recurrence.
Adjuvant therapy is often considered as part of the 
clinical management for post operative CCA where there are 
positive margins given the high rate of recurrence in these 
circumstances (28). Studies have reported survival benefits for 
chemoradiotherapy with incompletely resected tumors (3,29). 
A recent study looking at chemoradiation with 5‑fluorouracil 
(5-FU) and external beam irradiation reported improved 
survival for distal tumors particularly in patients with histo-
logically positive resection (30,31). It has been reported that 
gemcitabine-based approaches have better survival outcomes 
than 5-FU and should be considered as part of the clinical 
intervention (13). A recent report demonstrated that a low 
bilirubin level <10 mg/dl and chemotherapy administration are 
independent predictors associated with better survival (32).
Despite the genetic heterogeneity of CCA, perturbation 
of the RAS-MAPK pathway has been increasingly viewed 
as a potential signature genetic aberration in CCA (33-37). 
In Trinidad and Tobago, CCA provides an opportunity to 
integrate epidemiological data, genomics, and novel clinical 
approaches to better screen and treat CCA cases (38). One 
such schema integrates diagnostic tests, and identification 
of targetable cancer driver pathways leading to personalized 
targeted therapy (33,34).
In conclusion, the present case demonstrates clearly that 
intra-operative assessment of margins in resection of CCA are 
paramount. Aggressive surgical resection followed by adju-
vant therapy shows a definitive survival advantage. This case 
presented challenges given the difficulties to obtain a correct 
preoperative diagnosis, and to achieve R0 margins. Further 
studies are required to identify modalities to better diagnose 
and clinically intervene in these cases.
Acknowledgements
The authors of the present study appreciate the contributions 
of the Department of Pathology, Eric Williams Medical 
Sciences Complex, Trinidad and the assistance of Krishna 
Vyas, Washington University, St. Louis, USA with figure 
preparation. WAW was supported by Washington University 
School of Medicine-St. Louis (grant no., GSAS/CGFP Fund 
94028C).
References
 1. Steiner PE: Carcinoma of the liver in the United States. Acta 
Unio Int Contra Cancrum 13: 628-645, 1957. 
 2. Esposito I and Schirmacher P: Pathological aspects of cholangio-
carcinoma. HPB (Oxford) 10: 83-86, 2008.
 3. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, 
Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ and Cameron JL: 
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and 
distal tumors. Ann Surg 224: 463-475, 1996.
 4. Klöppel G, Adsay V, Konukiewitz B, Kleeff J, Schlitter AM and 
Esposito I: Precancerous lesions of the biliary tree. Best Pract 
Res Clin Gastroenterol 27: 285-297, 2013. 
 5. Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, 
Belli G, Bresadola F, Calise F, Dalla Valle R, D'Amico DF, et al: 
Improvement in perioperative and long-term outcome after 
surgical treatment of hilar cholangiocarcinoma: Results of an 
Italian multicenter analysis of 440 patients. Arch Surg 147: 
26-34, 2012. 
 6. Yamamoto M and Ariizumi S: Surgical outcomes of intrahepatic 
cholangiocarcinoma. Surg Today 41: 896-902, 2011.
 7. Rizvi S and Gores GJ: Pathogenesis, diagnosis, and 
management of cholangiocarcinoma. Gastroenterology 145: 
1215-1229, 2013.
 8. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, 
Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, 
Thillainayagam AV, et al: Guidelines for the diagnosis and 
treatment of cholangiocarcinoma: An update. Gut 61: 1657-1669, 
2012.
 9. Parkin DM, Ohshima H, Srivatanakul P and Vatanasapt V: 
Cholangiocarcinoma: Epidemiology, mechanisms of carcino-
genesis and prevention. Cancer Epidemiol Biomarkers Prev 2: 
537-544, 1993.
10. Chung YE, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC, Cho HJ, 
Kim KA and Choi SY: Varying appearances of cholangiocar-
cinoma: Radiologic-pathologic correlation. Radiographics 29: 
683-700, 2009. 
11. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, 
Davila JA and McGlynn KA: Risk factors for intrahepatic and 
extrahepatic cholangiocarcinoma in the United States: A popu-
lation-based case-control study. Clin Gastroenterol Hepatol 5: 
1221-1228, 2007.
12. Lazar idis KN and Gores GJ: Cholangiocarcinoma. 
Gastroenterology 128: 1655-1667, 2005.
13. Reddy SB and Patel T: Current approaches to the diagnosis and 
treatment of cholangiocarcinoma. Curr Gastroenterol Rep 8: 
30-37, 2006.
14. Shaib YH, El-Serag HB, Davila JA, Morgan R and McGlynn KA: 
Risk factors of intrahepatic cholangiocarcinoma in the United 
States: A case-control study. Gastroenterology 128: 620-626, 2005.
15. El Rassi ZE, Partensky C, Scoazec JY, Henry L, Lombard-Bohas C 
and Maddern G: Peripheral cholangiocarcinoma: Presentation, 
diagnosis, pathology and management. Eur J Surg Oncol 25: 
375-380, 1999.
16. Ito K, Ito H, Allen PJ, Gonen M, Klimstra D, D'Angelica MI, 
Fong Y, DeMatteo RP, Brennan MF, Blumgart LH and 
Jarnagin WR: Adequate lymph node assessment for extrahepatic 
bile duct adenocarcinoma. Ann Surg 251: 675-681, 2010.
17. Hong SM, Pawlik TM, Cho H, Aggarwal B, Goggins M, 
Hruban RH and Anders RA: Depth of tumor invasion better 
predicts prognosis than the current American joint committee 
on cancer T classification for distal bile duct carcinoma. 
Surgery 146: 250-257, 2009.
18. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Shibata K, 
Ishio T and Kitano S: Lymphatic spread differs according 
to tumor location in extrahepatic bi le duct cancer. 
Hepatogastroenterology 50: 17-20, 2003.
19. Ebata T, Nagino M, Nishio H, Igami T, Yokoyama Y and 
Nimura Y: Pancreatic and duodenal invasion in distal bile duct 
cancer: Paradox in the tumor classification of the American joint 
committee on cancer. World J Surg 31: 2008-2015,2007.
20. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H and 
Sueda T: Pancreatoduodenectomy for distal cholangiocarcinoma: 
Prognostic impact of lymph node metastasis. World J Surg 31: 
337-344, 2007.
21. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M and 
Kitano S: Prognostic factors after pancreatoduodenectomy with 
extended lymphadenectomy for distal bile duct cancer. Arch 
Surg 137: 69-73, 2002.
22. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, 
Ohge H and Sueda T: Prognostic significance of lymph node 
metastasis and surgical margin status for distal cholangiocar-
cinoma. J Surg Oncol 95: 207-212, 2007.
23. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, Jang JY, 
Kim SW, Kang GH and Yoon YB: Recurrence and prog-
nostic factors of ampullary carcinoma after radical resection: 
Comparison with distal extrahepatic cholangiocarcinoma. Ann 
Surg Oncol 14: 3195-3201, 2007.
24. Sasaki R, Takeda Y, Funato O, Nitta H, Kawamura H, Uesugi N, 
Sugai T, Wakabayashi G and Ohkohchi N: Significance of ductal 
margin status in patients undergoing surgical resection for extra-
hepatic cholangiocarcinoma. World J Surg 31: 1788-1796, 2007.
25. Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, 
Yamamoto H, Hayakawa N and Nimura Y: Lymph node 
metastasis from hilar cholangiocarcinoma: Audit of 110 patients 
who underwent regional and paraaortic node dissection. Ann 
Surg 233: 385-392, 2001.
26. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, 
Bodniewicz BS J, Youssef BA M, Klimstra D and Blumgart LH: 
Staging, resectability, and outcome in 225 patients with hilar 
cholangiocarcinoma. Ann Surg 234: 507-519, 2001.
ONCOLOGY LETTERS  12:  4075-4079,  2016 4079
27. Soares KC, Kamel I, Cosgrove DP, Herman JM and Pawlik TM: 
Hilar cholangiocarcinoma: Diagnosis, treatment options, and 
management. Hepatobiliary Surg Nutr 3: 18-34, 2014. 
28. Brandi G, Venturi M, Pantaleo MA and Ercolani G; GICO: 
Cholangiocarcinoma: Current opinion on clinical practice diag-
nostic and therapeutic algorithms: A review of the literature and 
a long-standing experience of a referral center. Dig Liver Dis 48: 
231-241, 2016.
29. Serafini FM, Sachs D, Bloomston M, Carey LC, Karl RC, 
Murr MM and Rosemurgy AS: Location, not staging, of cholan-
giocarcinoma determines the role for adjuvant chemoradiation 
therapy. Am Surg 67: 839-844, 2001.
30. Anderson CD, Pinson CW, Berlin J and Chari RS: Diagnosis 
and treatment of cholangiocarcinoma. Oncologist 9: 43-57, 
2004.
31. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, 
Yeo CJ, Lillemore KD and Cameron JL: Perihilar cholangiocar-
cinoma. Postoperative radiotherapy does not improve survival. 
Ann Surg 221: 788-798, 1995.
32. Farhat MH, Shamseddine AI, Tawil AN, Berjawi G, Sidani C, 
Shamseddeen W and Barada KA: Prognostic factors in patients 
with advanced cholangiocarcinoma: Role of surgery, chemotherapy 
and body mass index. World J Gastroenterol 14: 3224-3230, 2008.
33. Razumilava N and Gores GJ: Cholangiocarcinoma. Lancet 383: 
2168-2179, 2014.
34. Geynisman DM and Catenacci DV: Toward personalized 
treatment of advanced biliary tract cancers. Discov Med 14: 
41-57, 2012. 
35. Han W and Lo HW: Landscape of EGFR signaling network in 
human cancers: Biology and therapeutic response in relation to 
receptor subcellular locations. Cancer Lett 318: 124-134, 2012. 
36. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, 
Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, et al: 
Genomic and genetic characterization of cholangiocarcinoma 
identifies therapeutic targets for tyrosine kinase inhibitors. 
Gastroenterology 142: 1021-1031.e15, 2012. 
37. Brandi G, Farioli A, Astolfi A, Biasco G and Tavolari S: Genetic 
heterogeneity in cholangiocarcinoma: A major challenge for 
targeted therapies. Oncotarget 6: 14744-14753, 2015.
38. Roach A, Warner WA and Llanos AA: Building capacity for 
human genetics and genomics research in Trinidad and Tobago. 
Rev Panam Salud Publica 38: 425-430, 2015.
